|
PAPD5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.44089209850063E-16 |
| Normal-vs-Stage2 |
2.41349999985374E-08 |
| Normal-vs-Stage3 |
6.32827124036339E-15 |
| Normal-vs-Stage4 |
1.62980740014973E-12 |
| Stage1-vs-Stage2 |
6.747200E-01 |
| Stage1-vs-Stage3 |
4.090300E-02 |
| Stage1-vs-Stage4 |
3.641100E-03 |
| Stage2-vs-Stage3 |
8.856400E-02 |
| Stage2-vs-Stage4 |
6.160200E-03 |
| Stage3-vs-Stage4 |
2.095200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.67119999949783E-07 |
| Normal-vs-Asian |
6.57085497124399E-12 |
| Caucasian-vs-AfricanAmerican |
6.400200E-01 |
| Caucasian-vs-Asian |
4.666800E-01 |
| AfricanAmerican-vs-Asian |
9.786400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.87194704182048E-12 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
2.587400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.65645275274073E-12 |
| Normal-vs-Age(41-60Yrs) |
9.99200722162641E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62947433324234E-12 |
| Normal-vs-Age(81-100Yrs) |
6.37459999999201E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.346580E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.323640E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.221000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.850800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.197000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.995200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.771300E-04 |
| Classical-VS-Follicular |
8.038800E-01 |
| Classical-VS-Other |
7.788400E-01 |
| Classical-VS-Normal |
1.6242562850266E-12 |
| Tall-VS-Follicular |
2.995500E-03 |
| Tall-VS-Other |
3.680400E-01 |
| Tall-VS-Normal |
2.1094237467878E-14 |
| Follicular-VS-Other |
7.553800E-01 |
| Follicular-VS-Normal |
5.75600012098221E-10 |
| Other-VS-Normal |
2.176000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.22124532708767E-15 |
| Normal-vs-N1 |
5.48450174164827E-14 |
| N0-vs-N1 |
7.076400E-02 |
|
|
